Veracyte, Inc.
VCYT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $445,764 | $361,051 | $296,536 | $219,514 |
| % Growth | 23.5% | 21.8% | 35.1% | – |
| Cost of Goods Sold | $147,619 | $112,903 | $101,582 | $74,400 |
| Gross Profit | $298,145 | $248,148 | $194,954 | $145,114 |
| % Margin | 66.9% | 68.7% | 65.7% | 66.1% |
| R&D Expenses | $69,294 | $57,305 | $40,603 | $29,843 |
| G&A Expenses | $178,272 | $157,628 | $76,518 | $101,353 |
| SG&A Expenses | $206,044 | $184,232 | $174,078 | $181,193 |
| Sales & Mktg Exp. | $27,772 | $26,604 | $97,560 | $79,840 |
| Other Operating Expenses | $6,665 | $92,406 | $21,354 | $15,981 |
| Operating Expenses | $282,003 | $333,943 | $236,035 | $227,017 |
| Operating Income | $16,142 | -$85,795 | -$41,081 | -$81,903 |
| % Margin | 3.6% | -23.8% | -13.9% | -37.3% |
| Other Income/Exp. Net | $9,602 | $9,183 | $4,654 | $254 |
| Pre-Tax Income | $25,744 | -$76,612 | -$36,427 | -$81,649 |
| Tax Expense | $1,606 | -$2,208 | $133 | -$6,086 |
| Net Income | $24,138 | -$74,404 | -$36,560 | -$75,563 |
| % Margin | 5.4% | -20.6% | -12.3% | -34.4% |
| EPS | 0.32 | -1.02 | -0.51 | -1.11 |
| % Growth | 131.4% | -100% | 54.1% | – |
| EPS Diluted | 0.31 | -1.02 | -0.51 | -1.11 |
| Weighted Avg Shares Out | 76,485 | 72,644 | 71,549 | 67,890 |
| Weighted Avg Shares Out Dil | 78,163 | 72,644 | 71,549 | 67,890 |
| Supplemental Information | – | – | – | – |
| Interest Income | $11,154 | $7,344 | $1,972 | $135 |
| Interest Expense | $2 | $15 | $198 | $241 |
| Depreciation & Amortization | $23,459 | $27,188 | $29,248 | $21,225 |
| EBITDA | $49,205 | -$49,409 | -$6,981 | -$60,183 |
| % Margin | 11% | -13.7% | -2.4% | -27.4% |